However, in the ongoing exploration of advanced HCC and other cancers, immunotherapy methods increasingly focus on immune checkpoint inhibitors (ICIs), such as CTLA-4, PD-1 and PD-L1, which lock the immune checkpoint inhibition pathways (Kudo, 2019a). The gene discussed is PDCD1; the disease is cancer.